Background: The patient-doctor relationship (PDR) is a complex phenomenon with strong cultural determinants, which impacts health-related outcomes and, accordingly, does have ethical implications. The study objective was to describe the PDR from medical encounters between 600 Mexican outpatients with rheumatic diseases and their attending rheumatologists, and to identify factors associated with a good PDR.
Methods: A cross-sectional study was performed. Patients completed the PDRQ-9 (Patient-Doctor Relationship Questionnaire, 9 items), the HAQ-DI (Health Assessment Questionnaire Disability Index), the Short-Form 36 items (SF-36), a pain-visual analog scale, and the Ideal Patient Autonomy Scale. Relevant sociodemographic, disease-related, and treatment-related variables were obtained. Patients assigned a PDRQ-9 score to each patient-doctor encounter. Regression analysis was used to identify factors associated with a good PDR, which was defined based on a cutoff point established using the borderline performance method.
Results: Patients were primarily middle-aged female subjects (86%), with substantial disease duration (median, 11.1 years), without disability (HAQ-DI within reference range, 55.3%), and with deteriorated quality of life (SF-36 out of reference range, 73.7%-78.6%). Among them, 36.5% had systemic lupus erythematosus and 31.8% had rheumatoid arthritis. There were 422 patients (70.3%) with a good PDR and 523 medical encounters (87.2%) involved certified rheumatologists.Patient paternalistic ideal of autonomy (odds ratio [OR], 3.029; 95% confidence interval [CI], 1.793-5.113), SF-36 score (OR, 1.014; 95% CI, 1.003-1.025), female sex (OR, 0.460; 95% CI, 0.233-0.010), and being certified rheumatologist (OR, 1.526; 95% CI, 1.059-2.200) were associated with a good PDR.
Conclusions: Patient-related factors and the degree of experience of the attending physician impact the quality of the PDR, in Mexican outpatients with rheumatic diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169750 | PMC |
http://dx.doi.org/10.1097/RHU.0000000000001816 | DOI Listing |
J Cardiovasc Surg (Torino)
January 2025
Faculty of Medicine and Biomedical Sciences, Campus of Gambelas, University of Algarve, Faro, Portugal.
Background: Aortoiliac disease poses a significant cardiovascular (CV) risk, especially in individuals with chronic kidney disease. This study aimed to assess the predictive role of chronic kidney disease in long-term major adverse CV events in patients submitted to aortoiliac revascularization due to severe aortoiliac atherosclerotic disease.
Methods: From 2013 to 2023, patients who underwent aortoiliac revascularization for TASC II type D lesions, including those with chronic kidney disease, were selected from a prospective cohort study.
Allergol Immunopathol (Madr)
January 2025
Prince Sattam bin Abdulaziz Research Chair for Epidemiology and Public Health, Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: Asthma is considered one of the most common and serious noncommunicable diseases, with high morbidity and mortality rates in both children and adults.
Objectives: To estimate the frequency and to determine the associated factors of self-reported asthma among children diagnosed with type 1 diabetes.
Methods: A cross-sectional study design was employed, and 175 subjects having type 1 diabetes for more than 1 year were included from the pediatrics endocrine clinic.
Allergol Immunopathol (Madr)
January 2025
Research Department, Fundación Cardioinfantil, Bogotá, Colombia.
Background: Asthma, a chronic inflammatory lung disease, is one of the leading causes of disability, demands on health resources, and poor quality of life. It is necessary to identify asthma-related risk factors to reduce the presence and development of symptoms.
Objective: This study aimed to explore the association of multiple possible factors with asthma symptoms in two subpopulations, children, adolescents, and adults, in six cities in Colombia.
Allergol Immunopathol (Madr)
January 2025
Regional Center for Allergy and Clinical Immunology, University Hospital "Dr. José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico;
Background: Atopic dermatitis (AD) is a disease of multifactorial etiology that affects the quality of life of those afflicted.
Objective: The degree of control of patients with AD over 12 years of age was determined with the Atopic Dermatitis Control Instrument (ADCT).
Material And Methods: This observational, cross-sectional, descriptive study included patients with AD who were evaluated with a self-administered instrument, the ADCT.
Allergol Immunopathol (Madr)
January 2025
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!